[Skip to Content]
[Skip to Content Landing]
Views 3,543
Citations 0
Editorial
August 6, 2019

Screening for Pancreatic Cancer Gets a D, But the Student Is Improving

Author Affiliations
  • 1Sol Goldman Pancreatic Cancer Research Center, Departments of Pathology and Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland
  • 2Department of Surgery, Massachusetts General Hospital, Boston
JAMA Surg. Published online August 6, 2019. doi:10.1001/jamasurg.2019.2832

In the current issue of JAMA, the US Preventive Services Task Force (USPSTF) published a reaffirmation recommendation statement1 and evidence report and systematic review2 on pancreatic cancer screening. The report raises a number of provocative questions. Screening was given a D recommendation, meaning that the USPSTF recommends against screening for pancreatic cancer in asymptomatic adults. The USPSTF found that the available evidence indicated that there is moderate or high certainty that screening has no net benefit or that the harms outweigh the benefits. In this Editorial, we reflect on the conclusions of the USPSTF and look forward to new opportunities on the horizon.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×